	Application No.	Applicant(s)
Notice of Allowability	09/905,247	KË ET AL.
	Examiner	Art Unit
	Anand U. Desai, Ph.D.	1653
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>July 28, 2006</u> .		
2. The allowed claim(s) is/are 1,10,11,16 and 21-30.		
 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this national stage application from the 		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) 🔲 including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🗌 hereto or 2) 🗍 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/0. Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Summary (Paper No./Mail Date 8), 7. ⊠ Examiner's Amendm	e

Application/Control Number: 09/905,247

Art Unit: 1653

DETAILED ACTION

Page 2

1. This office action is in response to Amendment filed on July 28, 2006. Claim 9 has been cancelled. New claims 21-30 have been added. Claims 1, 10, 11, 16, and 21-30 are currently pending and are under examination.

EXAMINER'S AMENDMENT

2. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Howard M. Frankfort on September 15, 2006.

Examiners' amendment to the claims:

1. (Currently Amended) A mutant trichosanthin (MTCS) protein, comprising the amino acid sequence as set forth in SEQ ID NO: 8, comprising a with the modification of at least one amino acid residue in the region of amino acid residues 174 to 180, wherein said at least one amino acid residue modification is selected from the group consisting of: arginine at position 174 and lysine at position 177 are independently replaced with glutamic acid, aspartic acid, or glycine; aspartic acid at position 176 is independently replaced with lysine or glycine;

threonine at position 176 is independently replaced with lysine or glycine; threonine at position 178 is independently replaced with glycine or alanine, and valine at position 175, phenylalanine at position 179, and leucine at position 180 are independently deleted.

Art Unit: 1653

Conclusion

- 3. Claims 1, 10, 11, 16, and 21-30 are allowable.
- 4. The following is an examiner's statement of reasons for allowance:

The prior art does not describe a mutant trichosanthin protein comprising SEQ ID NO: 8, comprising a modification of at least one amino acid residue in the region of amino acid residues 174 to 180. He et al. (IDS document) disclose the modification of trichosanthin at position 219 with cysteine to reduce the immunogenicity. The modified trichosanthin is conjugated with polyethylene glycol to increase the plasma half-life using the modified cysteine residue.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anand U. Desai, Ph.D. whose telephone number is (571) 272-0947. The examiner can normally be reached on Monday - Friday 9:00 a.m. - 5:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon P. Weber can be reached on (517) 272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

September 18, 2006

ROBERT A. WAX
PRIMARY EXAMINER